Journal article : Review
Bridging the translational gap: what can synaptopathies tell us about autism?
- Abstract:
- Multiple molecular pathways and cellular processes have been implicated in the neurobiology of autism and other neurodevelopmental conditions. There is a current focus on synaptic gene conditions, or synaptopathies, which refer to clinical conditions associated with rare genetic variants disrupting genes involved in synaptic biology. Synaptopathies are commonly associated with autism and developmental delay and may be associated with a range of other neuropsychiatric outcomes. Altered synaptic biology is suggested by both preclinical and clinical studies in autism based on evidence of differences in early brain structural development and altered glutamatergic and GABAergic neurotransmission potentially perturbing excitatory and inhibitory balance. This review focusses on the NRXN-NLGN-SHANK pathway, which is implicated in the synaptic assembly, trans-synaptic signalling, and synaptic functioning. We provide an overview of the insights from preclinical molecular studies of the pathway. Concentrating on NRXN1 deletion and SHANK3 mutations, we discuss emerging understanding of cellular processes and electrophysiology from induced pluripotent stem cells (iPSC) models derived from individuals with synaptopathies, neuroimaging and behavioural findings in animal models of Nrxn1 and Shank3 synaptic gene conditions, and key findings regarding autism features, brain and behavioural phenotypes from human clinical studies of synaptopathies. The identification of molecular-based biomarkers from preclinical models aims to advance the development of targeted therapeutic treatments. However, it remains challenging to translate preclinical animal models and iPSC studies to interpret human brain development and autism features. We discuss the existing challenges in preclinical and clinical synaptopathy research, and potential solutions to align methodologies across preclinical and clinical research. Bridging the translational gap between preclinical and clinical studies will be necessary to understand biological mechanisms, to identify targeted therapies, and ultimately to progress towards personalised approaches for complex neurodevelopmental conditions such as autism.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 3.6MB, Terms of use)
-
- Publisher copy:
- 10.3389/fnmol.2023.1191323
Authors
- Publisher:
- Frontiers Media
- Journal:
- Frontiers in Molecular Neuroscience More from this journal
- Volume:
- 16
- Article number:
- 1191323
- Publication date:
- 2023-06-27
- Acceptance date:
- 2023-05-24
- DOI:
- EISSN:
-
1662-5099
- Pmid:
-
37441676
- Language:
-
English
- Keywords:
- Subtype:
-
Review
- Pubs id:
-
1493674
- Local pid:
-
pubs:1493674
- Deposit date:
-
2023-12-05
Terms of use
- Copyright holder:
- Molloy et al.
- Copyright date:
- 2023
- Rights statement:
- Copyright © 2023 Molloy, Cooke, Gatford, Rivera-Olvera, Avazzadeh, Homberg, Grandjean, Fernandes, Shen, Loth, Srivastava and Gallagher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record